Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?
about
Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzymeUse of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysisCerebrovascular disease in ageing and Alzheimer's diseaseDopamine Receptors and NeurodegenerationA Role for the Brain RAS in Alzheimer's and Parkinson's DiseasesWhat have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders?Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burdenBrain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration.An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3.Time trends in the use of anti-hypertensive medications: results from the Multi-Ethnic Study of Atherosclerosis.The neurovascular unit in brain function and disease.The association of angiotensin-converting enzyme with biomarkers for Alzheimer's diseaseBrain renin-angiotensin system and dopaminergic cell vulnerabilityPilot data on telmisartan short-term effects on glucose metabolism in the olfactory tract in Alzheimer's disease.A Comparison of Cognitive and Everyday Functional Performance among Older Adults With and Without Hypertension.AVR/NAVR deficiency lowers blood pressure and differentially affects urinary concentrating ability, cognition, and anxiety-like behavior in male and female micePharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme.Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink.Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra.Administration of bovine casein-derived peptide prevents cognitive decline in Alzheimer disease model mice.A complex dietary supplement augments spatial learning, brain mass, and mitochondrial electron transport chain activity in aging mice.Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's diseaseExpression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin-angiotensin system in the nigraAngiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging.Predictors of cognitive decline in older individuals with diabetes.High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey.Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment.Current and future therapy in Alzheimer's disease.Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia.The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease.Inhibition of the renin-angiotensin system and target organ protection.Current concepts in vascular cognitive impairment and pharmacotherapeutic implications.Angiotensins and Alzheimer's disease: a bench to bedside overviewEffects of angiotensin II receptor blockers on dementia.Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease.Non-adherence to antihypertensive medication and impaired cognition: which comes first?Current perspectives on pharmacotherapy of Alzheimer's disease.Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases.
P2860
Q24317730-307E85AC-DBA5-4C64-8379-3BF1DB66ED21Q24646726-A3B23A05-D232-44B0-9899-7D91BE34A3F1Q26771852-A7D3FC8F-82B1-470C-B72B-221F4793D6B7Q26783348-2B688BB1-9FD3-4493-AF48-BB0A3B10AB10Q26861984-E03D5BC5-81AA-4564-9AAE-7E80FBEC3CEAQ27025597-976645DF-07DC-4286-949F-60A723D0BBB8Q28074728-B862CE7F-296B-429F-8AC2-C39D9BBF15C9Q33627982-BD4EECD3-CA81-497E-8F9B-01992F35F153Q33652202-0AEE7A3B-7BF6-400A-98C4-B77A3D754C3FQ33748375-19A7F53A-E2AC-47F5-86E5-65093F03BEACQ33805295-00459C10-A1B7-4B36-8EAD-2A30FB5F3932Q33821846-84994CB8-DCA2-4E64-BDDB-1CCF19E08E39Q33861951-6B0D279B-E21F-4360-9113-4B8626E6E38FQ34187919-94B27127-7CF2-4995-9AA4-89C514173559Q34399201-D4D88630-F72D-461F-B08C-040AABDA51E9Q34518023-8D185E92-65B7-4AE7-BB48-DD64ECCECF45Q34994915-62528595-C530-474F-B5D7-8E1D76D0826FQ35023755-3810F98C-9242-46C6-BD22-D0B928B1F24FQ35806742-D5DAB145-41B4-4FE2-8B85-65A20A15A974Q36270062-BBE3DA74-1808-45B8-BDFB-A6787347E498Q36528260-5888B8A7-3E53-4B7F-8F0C-618C55241DA7Q36576477-85B3BF15-98FE-488B-825C-CAB1120D820CQ36576487-DCC9CC6D-BBFA-48BB-8B6D-C1DA29C26978Q36632049-C4680796-4A44-46D2-AA60-1AE9768701E5Q36670162-A8434BC1-6FCB-4FAA-BCE5-7C5168C2D45CQ36945266-B93D73CA-AC9B-4A44-8933-51CE3C9347D8Q37038148-91F59E57-5D97-4B09-9BCA-DB0894C635FAQ37092266-BA2806F2-AB28-44B7-8D38-2E669C55AB91Q37165703-ADE6AF2B-A207-4650-8ECA-3B5301917A2BQ37347449-65920DF0-F467-4BAB-B07E-DE247D4DC41EQ37363586-0B0DBA27-7AF6-4B8B-9328-F81B6A4C054FQ37406883-68C82B92-A2BF-4258-BC1E-B206BECB294EQ37543915-E4220912-5847-444E-BC9A-FD3F979517DDQ37578775-CFDBD1C8-3AD8-4E1F-B96E-0A138A9C0795Q37591159-ED36BEA0-2BF8-46D5-BDE5-99BDFC4735D2Q37600876-FE1525A7-6282-48D6-82DB-FA32AD91E5BEQ37772498-AF7283A5-B63D-412B-8DB6-D1669A010E5BQ37788825-7DA9EDF9-CA59-49AB-8BE5-8FF721A060B5Q37827489-673A6C0E-572D-47EA-9EBB-9E72EE9B25CCQ38021079-9E5B6071-C3A3-4181-9E81-82CB4A24B59C
P2860
Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Is inhibition of the renin-ang ...... ption for Alzheimer's disease?
@ast
Is inhibition of the renin-ang ...... ption for Alzheimer's disease?
@en
Is inhibition of the renin-ang ...... ption for Alzheimer's disease?
@nl
type
label
Is inhibition of the renin-ang ...... ption for Alzheimer's disease?
@ast
Is inhibition of the renin-ang ...... ption for Alzheimer's disease?
@en
Is inhibition of the renin-ang ...... ption for Alzheimer's disease?
@nl
prefLabel
Is inhibition of the renin-ang ...... ption for Alzheimer's disease?
@ast
Is inhibition of the renin-ang ...... ption for Alzheimer's disease?
@en
Is inhibition of the renin-ang ...... ption for Alzheimer's disease?
@nl
P1433
P1476
Is inhibition of the renin-ang ...... ption for Alzheimer's disease?
@en
P2093
Gordon K Wilcock
Patrick G Kehoe
P304
P356
10.1016/S1474-4422(07)70077-7
P577
2007-04-01T00:00:00Z